Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
暂无分享,去创建一个
J. Blay | S. Litière | P. Rutkowski | A. Le Cesne | H. Gelderblom | A. Gronchi | J. Martín-Broto | I. Ray-Coquard | S. Stacchiotti | B. Vincenzi | A. Czarnecka | S. Piperno-Neumann | D. Katz | R. Flippot | G. Grignani | B. Kasper | F. Mazzeo | F. Duffaud | D. Stark | J. Sherriff | C. Chevreau | A. Estival | F. Tolomeo | A. Tuchscherer | R. Sanfilippo | L. D'ambrosio | N. Touati | W. Sents | Nathan Touati | L. D'Ambrosio